IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

Jia Dai1,2,*, Di-Fei Shen1,2,*, Zhou-Yan Bian1,2,*, Heng Zhou1,2, Hua-Wen Gan1,2, Jing Zong1,2, Wei Deng1,2, Yuan Yuan1,2, FangFang Li1,2, Qing-Qing Wu1,2, Lu Gao3, Rui Zhang1,2, Zhen-Guo Ma1,2, Hong-Liang Li1,2, Qi-Zhu Tang1,2+  

1 Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China, 2 Cardiovascular Research Institute of Wuhan University, Wuhan, China, 3 Department of Cardiology, Institute of Cardiovascular Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

Abstract

The inducible IkB kinase (IKKi/IKKδ) is a recently described serine-threonine IKK-related kinase. Previous studies have reported the role of IKKi in infectious diseases and cancer. However, its role in the cardiac response to pressure overload remains elusive. In this study, we investigated the effects of IKKi deficiency on the development of pathological cardiac hypertrophy using in vitro and in vivo models. First, we developed mouse models of pressure overload cardiac hypertrophy induced by pressure overload using aortic banding (AB). Four weeks after AB, cardiac function was then assessed through echocardiographic and hemodynamic measurements. Western blotting, real-time PCR and histological analyses were used to assess the pathological and molecular mechanisms. We observed that IKKi-deficient mice showed significantly enhanced cardiac hypertrophy, cardiac dysfunction, apoptosis and fibrosis compared with WT mice. Furthermore, we recently revealed that the IKKi-deficient mice spontaneously develop cardiac hypertrophy. Moreover, in vivo experiments showed that IKKi deficiency-induced cardiac hypertrophy was associated with the activation of the AKT and NF-κB signaling pathway in response to AB. In cultured cells, IKKi overexpression suppressed the activation of this pathway. In conclusion, we demonstrate that IKKi deficiency exacerbates cardiac hypertrophy by regulating the AKT and NF-κB signaling pathway.

Introduction

Heart failure (HF) is a debilitating disease with a high prevalence, morbidity and mortality [1,2,3,4,5]. Pathological cardiac hypertrophy is an important predecessor of heart failure that is characterized by cardiac dysfunction, cell enlargement, reactivation of foetal gene expression, impaired myocardial vascularization, phenotypic changes in the extracellular matrix and hyperplasia of fibrosis [6,7,8,9]. Recent studies have shown that signaling pathways and their associated molecules play complex and pivotal roles in the development of cardiac hypertrophy, including mitogen activated protein kinases (MAPKs), phosphatidylinositol 3-kinase (PI3K)/AKT and calcineurin/nuclear factor of activated T cells (NFAT) [10]. However, effective blockade of the hypertrophy and prevention of transition to congestive heart failure remain a challenge. Thus, the identification of signals and pathways involved in pathological hypertrophy would open the door for the development of future therapeutic interventions for heart failure.

Nuclear factor-κB (NF-κB) plays a critical role in the immune response and influences gene expression events that affect cell survival, apoptosis, differentiation, proliferation, cancer progression and development [11,12]. The NF-κB family of transcription factors includes five members, p30, p52, p65 (RelA), c-Rel, and RelB. These members share an N-terminal Rel homology domain (RHD), which is responsible for DNA binding and homo- and heterodimerization [11,12]. In the absence of a stimulus, NF-κB dimers normally combine with one of three typical IkB proteins, IkBα, IkBβ or IkBε, or the precursor protein p100. Stimulation with cytokines or other agonists results in the phosphorylation of IkB by the inhibitory-κB kinase (IKK) complex, which includes IKKα, IKKβ and IKKγ, triggering the degradation of IkB. Then, the freed NF-κB translocates to the nucleus, where it binds to and activates the promoters of the NF-κB responsive genes [11,12].

Recent studies have shown that NF-κB directly exerts its role or alternatively involved in G protein-coupled receptor agonist- or tumour necrosis factor (TNFα)-induced cardiac hypertrophy and pathological remodeling and fibrosis and NF-κB inhibition attenuates cardiac hypertrophy [13,14,15,16,17]. Furthermore, IKKβ-deficient mice exhibit cardiac dilation and dysfunction and lung congestion [18]. The inducible IkB kinase (IKKi/IKKδ) constitutes a constitutively active serine-threonine IKK-related kinase shares 31% amino acid identity with IKKβ in the highly conserved N-terminal kinase domain but differs from IKKβ in several...
IKKi Deficiency Promotes Cardiac Hypertrophy

Animals and animal models

All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals, which was published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the Animal Care and Use Committee of the Renmin Hospital of Wuhan University (protocol number: 00020390). Male KO mice (C57BL/6 background; knockout mice were purchased from Jackson Laboratory, No. 006908) and their wild-type (WT) littermates, which ranged in age from 8 to 10 weeks, were subjected to aortic banding (AB) as described previously [27]. Each mouse was anaesthetized with sodium pentobarbital (Sigma, 80 mg/kg, ip), and a horizontal skin incision was made at the level of 2–3 intercostal space. The descending aorta was isolated, and a 7.0 silk suture was wrapped around the aorta. A bent 26-gauge needle (for 25.5–27.5 g) or 27-gauge needle (for 23.5–25.5 g) was then placed next to the aorta, and the suture was tied snugly around the needle and the aorta. After ligature, the needle was quickly removed, the chest and skin were closed, and the mice were allowed to recover. Sham-operated mice underwent the same procedure without constriction. The adequacy of anesthesia was monitored during the surgical procedures by assessing the lack of the pedal withdrawal reflex, slow constant breathing, and no response to surgical manipulation. Buprenorphine (0.1 mg/kg, sc) was administered for post-operative analgesia. Four weeks after the operation, the hearts, lungs, and tibiae of the mice were dissected and weighed or measured to compare the heart weight (HW)/body weight (BW) (mg/g), HW/tibia length (TL) (mg/mm), and lung weight (LW)/BW (mg/g) ratios of the different groups.

Echocardiography and hemodynamic analyses

Echocardiography was performed on anesthetized (1.5% isoflurane) mice using a MyLab 30CV (ESAOTE S. P. A) with a 15 MHz linear array ultrasound transducer. The left ventricle (LV) dimensions were assessed in the parasternal short-axis view. End-systole and end-diastole were defined as the phases that were associated with the smallest and largest areas of the LV, respectively. The end-systolic (LVESD) and end-diastolic (LVEDD) LV internal diameters and posterior wall end-diastolic thickness (PWT) were measured from the LV M-mode tracing with a sweep speed of 50 mm/s at the mid-papillary muscle level. The percentage of fractional shortening (FS) was calculated as (LVEDD-LVESD)/LVEDD x 100.

To perform the invasive hemodynamic measurements, we anesthetized the mice with 1.5% isoflurane, and a microtip transducer catheter (SPR-839, Millar Instruments, Houston, TX, USA) was inserted into the right carotid artery and advanced into the left ventricle. The pressure signals and heart rates were recorded continuously using a Millar Pressure-Volume System (MPV8-400, Millar Instruments, Houston, TX, USA), and the recordings were further analyzed using PVAN data analysis software.

Histological analysis and apoptotic cell assay

The hearts were excised, washed with PBS, arrested in diastole with 10% potassium chloride solution, weighed, placed in 10% formalin, and embedded in paraffin. They were then cut transversely and close to the apex to visualize the left and right ventricles. Several sections of each heart (4–5 μm thick) were prepared, stained with hematoxylin and eosin (H&E) for histopathology or picrosirius red (PSR) for collagen deposition by standard procedures and then visualized by light microscopy. For the myocyte cross-sectional area, sections were stained for membranes with FITC-conjugated WGA (Invitrogen) and for nuclei with DAPI. Single myocytes were measured using a quantitative digital image analysis system (Image Pro-Plus, version 6.0). The outlines of 100 myocytes were traced for each group. Cell death by apoptosis was evaluated using a TUNEL assay, which was performed on sections with In Situ Apoptosis Detection Kit (Roche, 1164817910) according to the manufacturer’s recommendations.

Quantitative real-time RT-PCR

Real-time PCR was performed to detect the mRNA expression levels of hypertrophic and fibrotic markers. Total RNA was extracted from frozen pulverized mouse cardiac tissue using TRIzol (Invitrogen, 15596-026). The yields and purities were spectrophotometrically estimated using the A260/A280 and A230/260 ratios, as measured with a SmartSpec Plus Spectrophotometer (Bio-Rad). The RNA (2 μg of each sample) was reverse-transcribed into cDNA using oligo(dT) primers and the Transcripter First Strand cDNA Synthesis Kit (Roche, 04986966001). The PCR amplifications were quantified using the LightCycler 480 SYBR Green 1 Master Mix (Roche,04707516001). The results were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression.

Protein extraction and western blotting analyses

The left ventricles were harvested for western blotting analyses. They were first lysed in RIPA lysis buffer, and the protein concentrations were measured using the BCA Protein Assay Kit (Thermo, 23227) and an ELISA Reader(Synergy HT, Bio-Tek). The cell lysates (50 μg) were loaded into each lane and subjected to SDS-PAGE, and the proteins were then transferred onto Immobilon-FL transfer membranes (Millipore, IFPL00010). The membranes were incubated overnight at 4°C with primary antibodies against one of the following proteins: p-MEK1/2 (Cat.#, 9154), T-MEK1/2 (Cat.#, 9122), p-ERK1/2 (Cat.#, 4370), T-ERK1/2 (Cat.#, 4695), p-P38 (Cat.#, 4511), T-P38 (Cat.#, 9212), p-JNK (Cat.#, 4668), T-JNK (Cat.#, 9258), p-PI3K (Cat.#, 4228), T-PI3K (Cat.#, 4257), p-AKT (Cat.#, 4060), T-AKT (Cat.#, 4691), p-GSK3β (Cat.#, 9322), T-GSK3β (Cat.#, 9315), p-MTOR (Cat.#, 2971), T-mTOR (Cat.#, 2983), p-FOXO3A (Cat.#, 9465), T-FOXO3A (Cat.#, 2497), p-FOXO1 (Cat.#, 9461), T-FOXO1 (Cat.#, 2880), p-NFκB (Cat.#, 3033), T-NFκB (Cat.#, 4764), Bax (Cat.#, 2772), Bcl2 (Cat.#, 2870), Cleaved Caspase3 (Cat.#, 9661), GAPDH (Cat.#, 2118), and IKKi (Cat.#, 3416). All antibodies were purchased from Cell Signaling Technology. The membranes were then incubated with goat anti-rabbit IgG (LI-COR, 926-32211) for one hour IgG. The blots were scanned using a two-color infrared imaging system (Odyssey, LI-COR).
protein expression levels were normalized to the GAPDH protein for the total cell lysates and cytosolic proteins.

**H9c2 cell culture and surface area**

Cultures of H9c2 rat cardiomyocyte cells (ATCC, Rockville, MD, USA) were prepared as described previously [28]. H9c2 cells were seeded at a density of 1 × 10^6 cells/well onto 6-well culture plates in Dulbecco's modified Eagle's medium (DMEM/F12 1:1 medium mixed at a ratio of 1:1 (v/v)) (Gibco, C11993) with 10% fetal bovine serum (FBS; Gibco, 1133067), penicillin (100 IU/ml), streptomycin (100 mg/ml), and L-glutamine (2 mmol/L). After 48 hours, the culture medium was replaced with F10 medium containing 0.1% FBS, and the cells were infected with different adenoviruses followed by angiotensin II (Ang II; 1 μM) treatment. For the cell infections, cardiac myocytes were cultured in 6-well plates at a density of 1 × 10^6 cells/well and then exposed to 2 × 10^8 pfu of each virus in 1 ml of serum-free medium for 24 hours. The cells were then washed and incubated in serum-containing medium for 24 hours. The virus Ad-IKKi was used to overexpress IKKi, and the control virus AdGFP was used as a control.

To identify the cardiomyocytes and assess cardiomyocyte hypertrophy, we characterized the cells by analyzing their cardiac α-actinin expression using immunofluorescence. The cells were washed with PBS, fixed with RCL2 (ALPHELYYS, RCL2-CS24L), permeabilized in 0.1% Triton X-100 in PBS, and stained with anti-α-actinin (Millipore, 05-384) at a dilution of 1:100 in 1% goat serum. The secondary antibody was Alexa Fluor® 488 goat anti-mouse IgG (Invitrogen, A11004). The myocytes on coverslips were mounted onto glass slides with SlowFade Gold antifade reagent with DAPI (Invitrogen, S36939).

**Statistical analysis**

Data are expressed as the means ± SEM. Differences among the groups were determined by a two-way ANOVA followed by a post hoc Tukey’s test. Comparisons between two groups were performed using an unpaired Student’s t-test. A p-value of <0.05 was considered to be statistically significant.

**Results**

**IKKi expression is induced in hypertrophic hearts following AB**

To investigate the potential role of IKKi in cardiac hypertrophy, we used the well-established cardiac hypertrophy model induced by AB. We found that IKKi protein and mRNA levels were slightly increased at 1 week but significantly up-regulated at 4 and 8 weeks after AB (Figure 1). These findings demonstrate that IKKi expression compensatorily increases during the development of cardiac hypertrophy.

**IKKi deficiency induces severe and spontaneous hypertrophy**

To evaluate alterations in cardiac structures and functions in IKKi-deficient mice, we harvested the hearts of 30-week-old mice and performed echocardiograms. It was documented that the HW, HW/BW, HW/TL, LVEDD, and LVESD were significantly increased and the FS was decreased compared with the WT mouse (Table 1), which agrees with our hypothesis that the loss of IKKi leads to spontaneous cardiac hypertrophy and dysfunction.

**IKKi deficiency enhances cardiac hypertrophic and dysfunctional responses to pressure overload**

To clarify the direct relationship between IKKi deficiency-mediated changes and cardiac hypertrophy, IKKi-KO mice and their WT littermates were subjected to cardiac pressure overload by AB or a sham surgery. The cumulative survival rate at 4 weeks after AB was strikingly decreased by IKKi deficiency (Figure 2E).

**Table 1. Anatomic and echocardiographic analysis of 24- to 30-week-old IKKi KO mice and WT mice.**

| Parameter           | WT (n = 6)     | IKKi KO (n = 6) |
|---------------------|----------------|-----------------|
| BW (g)              | 30.39 ± 0.66   | 31.08 ± 0.73    |
| HW/BW (mg/g)        | 4.05 ± 0.09    | 5.43 ± 0.22*    |
| LW/BW (mg/g)        | 4.67 ± 0.15    | 4.44 ± 0.16     |
| HW/TL (mg/cm)       | 6.54 ± 0.24    | 9.10 ± 0.32*    |
| HR (beats/min)      | 501 ± 12       | 520 ± 23        |
| LVEDD (mm)          | 3.53 ± 0.05    | 4.25 ± 0.11*    |
| LVESD (mm)          | 2.08 ± 0.06    | 2.78 ± 0.12*    |
| LVPW D (mm)         | 0.72 ± 0.01    | 0.73 ± 0.02*    |
| FS (%)              | 41.22 ± 1.28   | 34 ± 1.18*      |

BW, body weight; HW, heart weight; BW, body weight; LW, lung weight; HW/BW, heart weight/body weight; HW/TL, heart weight/rib/tibial length; HR, heart rate; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic diameter; LVPW D, left ventricular posterior wall dimension; VPD, Interventricular septal thickness at end-diastole; FS, fractional shortening.

*P < 0.05 vs WT/KO.
doi:10.1371/journal.pone.0053412.g001
Echocardiographic analyses were also utilized to evaluate cardiac structures and functions, including the chamber diameter, wall thicknesses and function of the left ventricle. The KO and WT mice that underwent sham surgery did not differ echocardiographically. However, the echocardiographic measurements of LVEDD, LVEDD, interventricular septal thickness at end-diastole (IVSd), left ventricular posterior wall thickness at end-diastole (LVPWd), and fractional shortening (FS) indicated deteriorated cardiac hypertrophy and dysfunction in the KO mice compared with the WT mice (Figure 2A). The LV hemodynamic parameters of the anesthetized mice that were obtained during the acquisition of the pressure-volume (PV) loop further confirmed this significantly deteriorated hemodynamic dysfunction (volume and systolic and diastolic function) of the LV in the IKKi-KO mice as shown in Table 2. Under basal conditions, pressure-overloaded KO mice showed significantly increased ratios of HW/BW, HW/TL, and LW/BW and cardiomyocyte cross-sectional area (CSA) compared with the WT mice. No significant differences were observed between the sham-operated groups (Figure 2B). The gross hearts and H&E and WGA staining results were also consistent with the role of IKKi as an inhibitor of cardiac hypertrophy (Figure 2D). Furthermore, real-time PCR was performed to analyze the mRNA expression of hypertrophic markers (Figure 2D). As expected, we found significantly higher expression levels of the cardiac fetal genes atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC) in the KO mice in response to AB. However, the mRNA expression levels of α-myosin heavy chain (α-MHC) and sarcoendoplasmic reticulum Ca²⁺-ATPase (SERCA2a) were reduced. These results indicate that IKKi deficiency is responsible for the progressive hypertrophic effects and the impairment of cardiac function that is induced by pressure overload.

**Forced IKKi expression attenuates the hypertrophic growth of myocytes in vitro**

To specifically examine the role of IKKi in cardiomyocytes, we performed gain-of-function studies using cultured H9c2 rat cardiomyocytes. The H9c2 cells were serum-starved for 24 h in 0.5% FBS after infection with Ad-IKKi and then treated with 1 μM Ang II for the indicated times. Ad-IKKi infection led to a substantial increase in the level of IKKi protein in H9c2 rat cardiomyocytes. Further studies showed that the IKKi overexpression induced by Ad-IKKi infection attenuated Ang II-mediated cardiomyocyte hypertrophy, as measured by the cell surface area (Figure 3A). Moreover, RT-PCR showed that IKKi overexpression markedly decreased the mRNA levels of ANP and BNP induced by Ang II (Figure 3B). These in vitro data suggest the inhibitory effect of IKKi on cardiomyocyte hypertrophy.

**IKKi deficiency significantly activates AKT/GSK3β/mTOR/FOXO and NF-kB signaling**

To elucidate the molecular mechanism by which IKKi deficiency mediates the hypertrophic response, we examined the activation state of AKT and the expression of its downstream targets, including GSK3β, mTOR, forkhead box O3A (FOXO3A), forkhead box O1 (FOXO1) and NF-kB using western blotting. The levels of phosphorylated AKT, GSK3β, mTOR, FOXO3A, FOXO1 and NF-kB were significantly increased in the hearts of the KO mice following pressure overload (Figures 4C, D). We then exposed cultured H9c2 cardiomyocytes infected with Ad-IKKi or Ad-GFP to 1 μM AngII. As shown in Figures 4E and F, AngII-stimulated AKT/GSK3β/mTOR/FOXO/NF-kB phosphorylation was attenuated by infection with Ad-IKKi. We further investigated the role of MAPK, another important signaling molecule that regulates the development of hypertrophy. However, the levels of phosphorylated MEK-ERK1/2, JNK, p38 and P38K were similar between the AB groups (Figures 4A, B).

**Effects of IKKi deficiency on cardiac fibrosis induced by pressure overload**

Fibrosis contributes to the phenotypic changes associated with the development of pathological cardiac hypertrophy. To detect the extent of fibrosis, we stained heart sections with PSR and found markedly increased perivascular and interstitial fibrosis and LV collagen volumes in the AB-induced KO and WT hearts compared with the sham-operated controls after 4 weeks. However, it should be noted that considerably increased cardiac fibrosis was also present in the KO mice (Figures 5A, B).

The observed interstitial fibrosis could be attributed to decreased collagen degradation or increased collagen synthesis. To evaluate the effect of IKKi on collagen synthesis, the mRNA expression levels of connective tissue growth factor (CTGF), transforming growth factor (TGF-β1, TGF-β2, collagen I, collagen III, and fibronectin), which are known mediators of fibrosis, were analyzed. Increased expression levels of CTGF, TGF-β1, TGF-β2, collagen I, collagen III, and fibronectin were detected in the AB-induced KO mice (Figure 5C). These data suggest that IKKi deficiency promotes cardiac fibrosis.

**IKKi deficiency enhances cardiac apoptosis induced by pressure overload**

To further explore the role of IKKi in hypertrophy, we assessed the apoptosis of myocytes after 4 weeks of AB using TUNEL assays. Apoptotic cells were detected in both KO and WT mice, and the fraction of apoptotic versus total cells was significantly higher in the pressure-overloaded hearts of the KO mice (Figures 6A,B). Furthermore, the levels of cleaved caspase 3, Bax (proapoptotic) and Bcl2 (antiapoptotic) proteins were assessed. The Bax protein level was increased and the Bcl2 protein level was decreased in the pressure-overloaded hearts of the KO mice, indicating a reduced Bcl2/Bax ratio. The level of cleaved caspase-3 was higher in the KO mice in response to AB (Figures 6C-E). These findings indicate that IKKi is involved in apoptosis in hypertrophic hearts subjected to pressure overload.

**Discussion**

Cardiac hypertrophy is characterized by the reactivation of fetal cardiac genes, increased cross-sectional areas of adult cardiomyocytes, and contractile dysfunction. In this study, we investigated the role of IKKi and its related molecular mechanisms in cardiac hypertrophy. The present study demonstrated that IKKi deficiency deteriorated cardiac hypertrophy and fibrosis. The important novel findings of our study are as follows: (1) IKKi expression is increased in AB-induced hypertrophic heart tissue; (2) IKKi deficiency provokes spontaneous hypertrophy; (3) IKKi deficiency promotes pathological hypertrophy and fibrosis; (4) IKKi overexpression markedly attenuates the hypertrophy of H9c2 rat cardiomyocytes induced by Ang II in vitro; (5) IKKi deficiency exacerbates cardiac remodeling by activating AKT and NF-κB signaling; and (6) IKKi deficiency is involved in apoptosis in hypertrophic hearts subjected to pressure overload.

As a member of the IKK family, IKKi (inducible IkB kinase), which is also known as IKKe, is involved in the activation of transcription factors [25]. Although IKKi is constitutively expressed in T cells, its expression is mainly regulated by NF-κB in other cell types [26]. Our data demonstrate that IKKi...
expression is significantly elevated in AB-induced hypertrophic heart tissues, which suggests that it is involved in promoting the development of cardiac hypertrophy and remodeling. This hypothesis is consistent with some studies involving other IKK family members, such as IKKβ [18].

The molecular mechanism by which IKKi affects cardiac remodeling remains unclear. To address this issue, we analyzed the activation of hypertrophic signaling pathways in AB mice. Pivotal signaling pathways that functioned in the pathogenesis of cardiac hypertrophy, including the mitogen-activated protein kinases (MAPKs) and AKT pathways, were assessed [10,27,29,30,31]. The downstream targets of AKT include GSK3β, mTOR, FOXO transcription factors and NFκB, all of which are involved in cardiac hypertrophy [10,27,29,30,31,32,33]. In this study, AKT phosphorylation was significantly enhanced in response to hypertrophic stimuli in the KO mice compared with WT mice. Consistent with the observed increase in AKT activity, hypertrophic stimuli caused increased levels of phosphorylated the GSK3βSer9 and FOXO transcription factors at AKT phosphorylation sites (reducing their anti-

hypertrophic effects) and increased activation of mTOR in the IKKi-deficient mice compared with WT mice. However, IKKi did not influence the phosphorylation of ERK1/2, JNK1/2, p38, MAPK or PI3K. Therefore, our study demonstrates that the AKT and NF-κB signaling is a critical pathway by which IKKi influences cardiomyocyte growth. Furthermore, we demonstrated that IKKi overexpression markedly inhibited AKT and NF-κB signaling in cultured cardiomyocytes stimulated by Ang II. However, the mechanism by which IKKi specifically activates AKT signaling remains unknown. In accordance with our findings, TRAF-associated NFκB activator-binding kinase1 (TBK1), another IkB kinase-related kinase, which exhibits 49% identity and 65% similarity to IKKi, another member of the IKK family, has been shown to control the activation of AKT [34,35]. As a ligand for integrins, the absence of IKKi may be compensated for by TBK1, thus modulating integrin signaling or a specific integrin complex in a manner that specifically regulates AKT. Further experiments are needed to determine the molecular signaling mechanism by which IKKi regulates AKT. It is worth noting that the AKT pathway is a non-specific

Figure 2. Effects of IKKi on cardiac hypertrophy. A, Echocardiographic results for the 4 groups of mice at 4 weeks following AB or sham surgery (n = 6). B, Statistical results of the HW/BW, LW/BW, and HW/TL ratios and myocyte cross-sectional areas of the indicated groups. C, Gross hearts, HE staining and WGA-FITC staining of the sham and AB mice at 4 weeks post-surgery. D, Expression levels of the transcripts of ANP, BNP, β-MHC, α-MHC and SERCA2a after AB were determined by RT-PCR analysis (n = 6). E. Kaplan-Meier curve depicting the survival of WT-sham, KO-sham, WT-AB, and KO-AB mice *P<0.05 vs. WT/sham, #P<0.05 vs. WT/AB following AB. doi:10.1371/journal.pone.0053412.g002

IKKi Deficiency Promotes Cardiac Hypertrophy
### Table 2. Anatomic and hemodynamic parameters in IKKi KO and WT mice at 4 weeks after surgery.

| Parameter                  | Sham WT(n = 6) | IKKi KO(n = 6) | AB WT(n = 6) | IKKi KO(n = 6) |
|----------------------------|----------------|----------------|--------------|----------------|
| BW (g)                     | 27.50 ± 0.52   | 27.19 ± 0.32   | 27.89 ± 0.34 | 28.02 ± 0.40   |
| HW/BW (mg/g)               | 4.29 ± 0.07    | 4.43 ± 0.04    | 6.49 ± 0.08* | 8.53 ± 0.42*#  |
| LW/BW (mg/g)               | 5.20 ± 0.05    | 4.90 ± 0.10    | 5.19 ± 0.13  | 9.33 ± 0.76*#  |
| HW/LW (mg/cm)              | 6.40 ± 0.13    | 6.51 ± 0.08    | 9.96 ± 0.08* | 12.83 ± 0.48*# |
| HR (beats/min)             | 483 ± 9        | 462 ± 10       | 477 ± 8      | 462 ± 18       |
| ESP (mmHg)                 | 105.74 ± 1.58  | 117.15 ± 4.04  | 150.85 ± 2.16* | 149.25 ± 2.30* |
| EDP (mmHg)                 | 9.84 ± 0.19    | 10.24 ± 1.28   | 17.75 ± 2.14* | 24.31 ± 1.84*# |
| ESV (ml)                   | 10.09 ± 0.44   | 10.51 ± 1.46   | 23.58 ± 1.93* | 37.23 ± 3.46*# |
| EDV (ml)                   | 26.82 ± 0.78   | 24.85 ± 1.83   | 34.44 ± 1.32* | 48.37 ± 3.29*# |
| dP/dt max (mmHg/s)         | 10585.47 ± 540.98 | 10663.83 ± 781.97 | 8171.17 ± 326.82* | 6694.33 ± 306.38*# |
| dP/dt min (mmHg/s)         | −9177.34 ± 269.63 | −8967.33 ± 357.21 | −7658.17 ± 346.37* | −6578.17 ± 416.63*# |
| EF(%)                      | 65.60 ± 1.35   | 64.02 ± 2.66   | 39.18 ± 2.40* | 25.83 ± 3.11*# |

BW, body weight; HW/BW, heart weight/body weight; LW/BW, lung weight/body weight; HW/TL, heart weight/tibial length; HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; dP/dt max, maximal rate of pressure development; dP/dt min, maximal rate of pressure decay.

* P < 0.05 vs WT/sham;
# P < 0.05 vs WT/AB after AB.

doi:10.1371/journal.pone.0053412.t002

---

**Figure 3. IKKi overexpression attenuates myocyte hypertrophy in vitro.**

A. The inhibitory effect of IKKi overexpression on the enlargement of myocyte induced by Ang II (1 μM for 48 h). B. RT-PCR analysis of the mRNA levels of ANP and BNP induced by Ang II at the time points indicated.

* P < 0.05 vs WT at the 0 time point. # P < 0.05 vs WT at the same time point.

doi:10.1371/journal.pone.0053412.g003
pathways, and a change in the AKT pathway is likely to be an indicator rather than a true determinant and a pharmacological target.

Fibrosis is an important contributor to the development of cardiac dysfunction in diverse pathological conditions. Fibrosis involves the progressive over-accumulation of extracellular matrix.
(ECM) (which surrounds and interconnects cells, is present in the myocardial wall and provides a scaffold for both myocytes and non-myocytes) components in cardiac muscle [36]. The major ECM proteins (type I and III collagens) are increasingly synthesized in the heart in response to pressure overload stimuli [36]. Moreover, the increased expression of TGF-β1 parallels the perivascular and myocardial interstitial fibrotic changes [37]. TGF-β and CTGF also modulate the proliferation of fibroblasts [30]. The present study has shown for the first time that IKKi deficiency leads to increased collagen deposition after AB and increased mRNA levels of CTGF, TGFβ and collagen I and III mRNA. These results suggest that IKKi deficiency promotes fibrosis and cardiac remodeling by enhancing collagen synthesis and up-regulating fibrotic mediators.

Cardiac myocyte apoptosis is also a critical factor during the transition from compensatory cardiac hypertrophy in response to pressure overload to heart failure [38]. The present study showed increased apoptosis in the pressure-overloaded hearts of the KO mice compared with the WT mice. Furthermore, our results also demonstrated a significant increase in the of Bax-to-Bc12
expression ratio and the activation of caspase-3 in the hearts of the KO mice after AB. Taken together, these data indicate that IKKi deficiency could influence apoptosis by affecting apoptosis-regulating proteins.

The roles of IKKi in the cardiac hypertrophic response to pressure overload have not been described previously. We are one step closer to elucidating the IKKi-related mechanisms that are associated with the development of cardiac hypertrophy, fibrosis and apoptosis. IKKi protects against hypertrophy via negative feedback of the AKT and NF-κB signaling pathway and concurrently regulates collagen deposition and fibrotic mediators.

Taken together, our findings provide a rationale for further studies on the potential therapeutic benefits of IKKi in cardiovascular disease.

**Author Contributions**
Conceived and designed the experiments: QT JD DS ZB HL. Performed the experiments: JD DS ZB HZ HG JZ RZ. Analyzed the data: JD WD YY FL QW LG ZM. Contributed reagents/materials/analysis tools: QT HL. Wrote the paper: JD DS ZB HL QT.

**References**
1. Tamargo J, Lopez-Sendon J (2011) Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 10: 536–555.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933–989.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1–e90.
4.loyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. (2010) Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121: 948–954.
5. Pazos-Lopez P, Peteiro-Vazquez J, Garcia-Campos A, Garcia-Bueno I, de Torres JP, et al. (2011) The causes, consequences, and treatment of left or right heart failure. Vasc Health Risk Manag 7: 237–254.
6. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, et al. (2001) Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am J Physiol Regul Integr Comp Physiol 281: R2029–R2036.
7. de Borr RA, Pinto YM, Van Veldhuisen DJ (2003) The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10: 113–126.

8. Olson EN (2004) A decade of discoveries in cardiac biology. Nat Med 10: 467–474.

9. Thumm T, Galuppo P, Wolf C, Fiedler J, Kneitz S, et al. (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116: 258–267.

10. Heinke J, Molkensteijn JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589–600.

11. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132: 344–362.

12. Shih VF, Tsai R, Caldwell A, Hoffmann A (2011) A single NF-kappaB system for both canonical and non-canonical signaling. Cell Res 21: 86–102.

13. Zelarayan L, Bulek K, Liu C, Swaidani S, Wang L, et al. (2011) IKKi: a novel regulator of Act1, IL-17 and NF-kappaB activation. Cell Mol Immunol 8: 447–449.

14. Hikoso S, Yamaguchi O, Nakano Y, Takeda T, Omiya S, et al. (2009) The inducible IkappaB kinase-related kinase IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 284: 416–424.

15. Higuchi Y, Fujishita K, Nakajima T, Nakayama H, et al. (2002) Regulation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 290: H590–H598.

16. Liu Q, Chen Y, Auger-Messier M, Molkentin JD (2012) Interaction between NF-kappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110: 1077–1086.

17. Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure. Circ Res 91: 1103–1113.

18. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ (2003) IKKepsilon/IKKbeta is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 12: 844–852.

19. Peart B, Forest V, Trudeau V, Latour M, Mes-Masson AM, et al. (2011) IkkappaB-Kinase-epsilon (IKKepsilon/IKKi/IkappaBKepsilon) expression and localization in prostate cancer tissues. Prostate 71: 1131–1138.

20. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Lutz E, et al. (2003) IKKepsilon and TBK1 are essential components of the IFN3 signaling pathway. Nat Immunol 4: 491–496.

21. Peters RT, Liao SM, Maniatis T (2000) IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 5: 513–522.

22. Li H, He C, Feng J, Zhang Y, Tang Q, et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818–13823.

23. Bulek K, Liu C, Swaidani S, Wang L, Page RG, et al. (2011) The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 12: 844–852.

24. Peart B, Forest V, Trudeau V, Latour M, Mes-Masson AM, et al. (2011) IkkappaB-Kinase-epsilon (IKKepsilon/IKKi/IkappaBKepsilon) expression and localization in prostate cancer tissues. Prostate 71: 1131–1138.

25. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Lutz E, et al. (2003) IKKepsilon and TBK1 are essential components of the IFN3 signaling pathway. Nat Immunol 4: 491–496.

26. Peters RT, Liao SM, Maniatis T (2000) IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 5: 513–522.

27. Li H, He C, Feng J, Zhang Y, Tang Q, et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818–13823.

28. Sambandam N, Steinmetz M, Chu A, Altarejos JY, Dyck JR, et al. (2004) Malonyl-CoA dehydrogenase (MCD) is differentially regulated in subcellular compartments by AMP-activated protein kinase (AMPK). Studies using H9c2 cells overexpressing MCD and AMPK by adeno viral gene transfer technique. Eur J Biochem 271: 2831–2840.

29. Bian ZY, Wei X, Deng S, Tang QZ, Feng J, et al. (2012) Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl).

30. Zhou H, Shen DF, Bui ZY, Zeng J, Deng W, et al. (2011) Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload. PLoS One 6: e25674.

31. Yan L, Wei X, Tang QZ, Feng J, Zhang Y, et al. (2011) Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking Akt/GSK3beta and TGF-beta1-Smad signaling. Cardiovasc Res 92: 83–94.

32. Sun HZ, Yang TW, Zang WJ, Wu SF (2010) Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PEIK/AKT signaling pathway. J Endocrinol 204: 311–318.

33. Higuchi Y, Chen TO, Brown MA, Zhang J, DeGeorge BJ, et al. (2006) Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 290: H590–H598.

34. Chau TL, Goea R, Gator JS, Patrascu F, Carpenter I, et al. (2008) Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 33: 171–180.

35. Joung SM, Park ZY, Rani S, Takeuchi O, Akira S, et al. (2011) Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol 180: 989–997.

36. Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91: 1103–1113.

37. Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiotzu M, et al. (2012) The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 35: 54–60.

38. Anilkumar N, Sirker A, Shah AM (2009) Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci 14: 3168–3187.